| INTRALYTIX, INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120148505 | Reduction In Bacterial Colonization By Administering Bacteriophage Compositions - The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage. | 06-14-2012 |
| 20100075398 | Bacteriophage Preparations and Method of Use Thereof - Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of | 03-25-2010 |
| 20100068787 | Novel Staphylococcus aureus: Bacteriophage and Uses Thereof - The present invention is directed to isolated bacteriophage having strong lytic activity against strains of | 03-18-2010 |
| 20090155329 | Novel E. coli Bacteriophage and Uses Thereof - The present invention is directed to isolated | 06-18-2009 |
| 20090155217 | Novel E. coli O157:H7 Bacteriophage and Uses Thereof - The present invention is directed to isolated bacteriophage having strong lytic activity against strains of | 06-18-2009 |
| 20090053144 | REDUCTION IN BACTERIAL COLONIZATION BY ADMINISTERING BACTERIOPHAGE COMPOSITIONS - The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage. | 02-26-2009 |
| 20090047727 | Novel Clostridium perfringens Bacteriophage and Uses Thereof - The present invention is directed to isolated bacteriophage having strong lytic activity against strains of | 02-19-2009 |
| 20090047726 | Novel Clostridium perfringens Bacteriophage and Uses Thereof - The present invention is directed to isolated bacteriophage having strong lytic activity against strains of | 02-19-2009 |
| 20080311643 | Novel Pseudomonas aeruginosa: Bacteriophage and Uses Thereof - The present invention is directed to isolated bacteriophage having strong lytic activity against strains of | 12-18-2008 |
| 20080299641 | Novel E. coli 0157:H7 bacteriophage and uses thereof - The present invention is directed to isolated bacteriophage having strong lytic activity against strains of | 12-04-2008 |
